The Cyssor reagent, 2-methyl-N1-benzenesulfonyl-N4-bromoacetylquinonediimide, which will cleave a protein chain at Cys under acidic conditions, cross-linked unreduced and partially reduced antibody at pH 8.0. No cleavage of the antibody occurred suggesting that the Cyssor reagent may be useful with certain proteins as a heterobifunctional cross-linker.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28052/1/0000491.pd
A series of reagents have been developed which can interact with nucleophilic sulfhydryl groups on p...
Disulfide bridging, also known as disulfide stapling, is a powerful strategy for the construction of...
Cleavable linkers are designed to release the drug within or in the vicinity of the tumour cells upo...
will cleave a protein chain at Cys under acidic conditions, cross-linked unreduced and partially red...
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilise the exquisite sele...
Conventional antibody–drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molec...
We describe investigations to expand the scope of next generation maleimide cross-linkers for the co...
Three different cross-linking reagents were examined for their ability to link two antibodies togeth...
The design and generation of complex multifunctional macromolecular structures by bioconjugation is ...
Monoclonal antibodies were raised that specifically recognize the NH2-terminal neoepitope sequence p...
Despite the advances in the design of antibody–drug conjugates (ADCs), the search is still ongoing f...
Monoclonal antibodies are routinely used in the clinic. There are also a small number of antibody fr...
Developing site-specific conjugation technologies for antibody–drug conjugates (ADCs) aims to produc...
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of...
Antibodies are immensely useful tools for biochemical research and have found application in numerou...
A series of reagents have been developed which can interact with nucleophilic sulfhydryl groups on p...
Disulfide bridging, also known as disulfide stapling, is a powerful strategy for the construction of...
Cleavable linkers are designed to release the drug within or in the vicinity of the tumour cells upo...
will cleave a protein chain at Cys under acidic conditions, cross-linked unreduced and partially red...
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilise the exquisite sele...
Conventional antibody–drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molec...
We describe investigations to expand the scope of next generation maleimide cross-linkers for the co...
Three different cross-linking reagents were examined for their ability to link two antibodies togeth...
The design and generation of complex multifunctional macromolecular structures by bioconjugation is ...
Monoclonal antibodies were raised that specifically recognize the NH2-terminal neoepitope sequence p...
Despite the advances in the design of antibody–drug conjugates (ADCs), the search is still ongoing f...
Monoclonal antibodies are routinely used in the clinic. There are also a small number of antibody fr...
Developing site-specific conjugation technologies for antibody–drug conjugates (ADCs) aims to produc...
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of...
Antibodies are immensely useful tools for biochemical research and have found application in numerou...
A series of reagents have been developed which can interact with nucleophilic sulfhydryl groups on p...
Disulfide bridging, also known as disulfide stapling, is a powerful strategy for the construction of...
Cleavable linkers are designed to release the drug within or in the vicinity of the tumour cells upo...